Company news

ACADIA Pharmaceuticals Inc. news in 2026

ACADIA Pharmaceuticals Inc.'s news releases, calls and decks from 2026, newest first.

View company

Acadia Pharmaceuticals Reports Third Quarter 2026 Financial Results

November 4, 2026

Acadia Pharmaceuticals to Participate in the UBS Global Biopharma Conference 2026

October 28, 2026

Acadia Pharmaceuticals to Announce Third Quarter 2026 Financial Results on November 4, 2026

October 21, 2026

Acadia Pharmaceuticals Announces Allowance of U.S. Patent Covering Weight-Banded Dosing of Trofinetide, extending U.S. patent protections to March 2041

September 28, 2026

Acadia Pharmaceuticals Announces Phase 3 Enabling Topline Results from Phase 2 RADIANT Study of Remlifanserin for the Treatment of Alzheimer’s Disease Psychosis (ADP)

September 24, 2026

European Commission Approves DAYBU® (trofinetide) as the First and Only Treatment for Neurobehavioral Symptoms of Rett Syndrome in the European Union

August 24, 2026

Acadia Pharmaceuticals Reports Second Quarter 2026 Financial Results

August 4, 2026

Acadia Pharmaceuticals to Participate in the Canaccord Genuity 46th Annual Growth Conference

July 30, 2026

Acadia Pharmaceuticals Receives FDA Fast Track Designation for Remlifanserin in Alzheimer's Disease Psychosis

July 20, 2026

Acadia Pharmaceuticals to Announce Second Quarter 2026 Financial Results on August 4, 2026

July 15, 2026

Acadia Pharmaceuticals Appoints Carl Segerstrom as Chief People Officer

July 6, 2026

DAYBU® (trofinetide) Recommended for Approval in the European Union by CHMP

June 26, 2026

Acadia Pharmaceuticals Reports First Quarter 2026 Financial Results and Reaffirms 2026 Financial Guidance

May 6, 2026

Acadia Pharmaceuticals Announces Planned Year-End Retirement of Elizabeth H.Z. Thompson, Ph.D., Head of Research and Development, Following a Distinguished Career

April 30, 2026

Acadia Pharmaceuticals to Present Data at the 2026 American Academy of Neurology (AAN) Annual Meeting

April 17, 2026

Acadia Pharmaceuticals to Announce First Quarter 2026 Financial Results on May 6, 2026

April 15, 2026

Acadia Pharmaceuticals Announces DAYBUE® STIX (trofinetide) is Now Broadly Available in the United States for the Treatment of Rett Syndrome

April 6, 2026

Acadia Pharmaceuticals to Participate in the Stifel 2026 Virtual CNS Forum

March 12, 2026

Acadia Pharmaceuticals Appoints Jonathan M. Poole to its Board of Directors

March 3, 2026

Acadia Pharmaceuticals Announces Plan to Request Re-Examination Following Negative CHMP Opinion for Trofinetide for the Treatment of Rett Syndrome

March 2, 2026

Acadia Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Operating Overview

February 24, 2026

Acadia Pharmaceuticals to Announce Fourth Quarter and Full Year 2025 Financial Results on February 25, 2026

February 4, 2026

Acadia Pharmaceuticals Provides Update on Regulatory Submission for Trofinetide for the Treatment of Rett Syndrome in the European Union

February 2, 2026

Acadia Pharmaceuticals Provides Business and Pipeline Updates at 44th Annual J.P. Morgan Healthcare Conference

January 12, 2026

Calls in 2026

Decks in 2026